# About BPC-157 Clinic — A Research-Summary Publication

> About this site: an independent editorial summary of the BPC-157 research literature. Not a clinic, not a vendor, not affiliated with any product.

An independent, citation-anchored summary of the BPC-157 literature. Not a clinic. Not a vendor. Not affiliated with any product.

## What this site is

*BPC157clinic.com* is a research-summary publication covering the preclinical and clinical literature on BPC-157 — also catalogued as Pentadecapeptide BPC 157, PL 14736, PL-10, and PLD-116. The site exists to make a thirty-year, single-lab-dominated, predominantly rodent literature legible to a reader who wants to know what was actually studied, at what dose, in what species, with what reported outcome.

The word *clinic* in the domain refers to clinical research — the published bench-and-pilot record — not to patient services. No medical care is provided through this site. No product is sold. No protocol is recommended. No affiliate or referral relationship exists between this site and any vendor of peptides, research chemicals, supplements, or compounded preparations.

## Editorial standards

*Standards.* Three rules govern what appears on this site:

*First*, every quantitative claim — every dose, every concentration, every percentage, every half-life — is anchored to a citation listed on the [references page](/references). Citations are to peer-reviewed journal articles indexed in PubMed, PMC, or the publisher's own DOI registry. Where a citation is to a review or commentary, the review is cited, not the underlying primary literature it summarizes.

*Second*, doses are reported in the species and route in which they were administered. A rat at 10 μg/kg intraperitoneal is described as such. The site does not perform allometric scaling. Where an author has proposed a human dose extrapolation (He et al., 2022), the proposal is reported as a single citation, not as guidance.

*Third*, no medical claim is made about any human indication. The peptide is not approved by the FDA, EMA, MHRA, TGA, or any other major regulatory authority. It is on the FDA's Category 2 list (September 2023) and on the WADA Prohibited List under section S0 (effective 1 January 2022). Both facts appear on the index, the research page, and the FAQ.

## What this site is not

It is not a clinic. It is not a treatment provider. It is not a peptide vendor or a vendor's affiliate. It does not collect identifying patient information. It is not a substitute for advice from a licensed clinician. It does not endorse, recommend, or facilitate any human use of BPC-157.

Readers interested in conditions described in the rodent literature — tendon and ligament injury, gastrointestinal anastomotic healing, fistula closure, ischemia-reperfusion, traumatic brain injury, peripheral nerve injury, spinal cord injury — are referred to a licensed clinician operating within their jurisdiction, working with regulated, evidence-based interventions.

## Disclaimer

*BPC157clinic.com* is a research-summary publication covering the BPC-157 literature. Nothing on this site constitutes medical advice, diagnosis, treatment recommendation, or an offer to sell any compound or preparation. BPC-157 is not approved by the FDA, EMA, or any other major regulatory authority for human use, and is prohibited under WADA section S0 for athletes subject to anti-doping rules. The site does not operate a clinic, dispense product, recommend doses, or refer to vendors. It does not collect identifying patient information.

---

An indexed editorial summary of the peer-reviewed BPC-157 literature — not a clinic, not a vendor, not a prescription.